A new analysis calls into question the use of imaging alone to determine the efficacy of ablative radiation therapy. 

Steven Bolling, MD, noted that tricuspid treatments have been linked to consistent benefits in terms of quality of life. However, he said, finding clear improvements in clinical outcomes has been more challenging.

The drug in question, ataciguat, could help heart patients avoid aortic valve replacement—or at least put it off until later in life.

Researchers tracked three years of CMS data to explore how meal-based marketing may influence the habits of general and advanced heart failure cardiologists.

CMS will cover TTVR for the treatment of symptomatic tricuspid regurgitation on a national level. The agency first proposed such a policy in December, taking time to consider public comments before finalizing its decision.

The FDA shared a warning about these safety issues in February, but said it was still reviewing the evidence. The agency is now saying the devices “may cause serious injury or death” if used without following the updated instructions for use.

Motivity is receiving an injection of cash from Five Elms Capital, a software investment firm. The companies said the funds will be used to hire staff and improve products.  

Using a left radial artery approach in the cath lab exposes interventional cardiologists to significantly less radiation than a hyper-adducted right radial artery approach. The difference is substantial enough for researchers to declare LRA "the primary access site for cardiac catheterization."